Cargando…
Critical appraisal of rotigotine transdermal system in management of Parkinson’s disease and restless legs syndrome – patient considerations
Rotigotine (RTG) is a dopamine agonist that is used as mono and adjunct therapy to treat Parkinson’s disease, and as therapy for moderate-to-severe restless legs syndrome. RTG is the only dopamine agonist currently available as a 24-hour/day transdermal system, providing once-a-day dosing. As a tran...
Autores principales: | Kesayan, Tigran, Shaw, Jessica D, Jones, Tracy M, Staffetti, Joseph S, Zesiewicz, Theresa A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7337197/ https://www.ncbi.nlm.nih.gov/pubmed/32669913 http://dx.doi.org/10.2147/DNND.S37268 |
Ejemplares similares
-
Critical appraisal of rotigotine transdermal system in management of Parkinson’s disease and restless legs syndrome – patient considerations [Corrigendum]
Publicado: (2016) -
Transdermal rotigotine for the perioperative management of restless legs syndrome
por: Högl, Birgit, et al.
Publicado: (2012) -
An Update on Pharmacological, Pharmacokinetic Properties and Drug–Drug Interactions of Rotigotine Transdermal System in Parkinson’s Disease and Restless Legs Syndrome
por: Elshoff, Jan-Peer, et al.
Publicado: (2015) -
Treatment of moderate to severe restless legs syndrome: 2-year safety and efficacy of rotigotine transdermal patch
por: Högl, Birgit, et al.
Publicado: (2010) -
Restless legs syndrome: differential diagnosis and management with rotigotine
por: Merlino, Giovanni, et al.
Publicado: (2009)